Dr John E. Kelly joining NanoDx, Inc as Technical and Strategic Advisor to the Board of Directors
It is immense pleasure that we announce the Dr. John E. Kelly, former Executive Vice President of IBM, will be joining NanoDx as a Technical and Strategic Advisor to the Board of Directors. Dr. Kelly will provide technical advice and assistance to the Company including strategic guidance, introduction to subject matter experts, evaluation of technical materials, and assessment of development roadmaps and progress reports. In his consulting role, Dr. Kelly will develop close working relationships with our Interim CEO, George Serafin, and our CSO, Dr. Sergey Dryga, and their supporting technical staff.
In December 2020, NanoDx obtained a worldwide licensing agreement from IBM Research for use of its metal-oxide semi-conductive (“CMOS”) compatible nanoscale sensors to enhance accurate, rapid testing while obtaining high throughput at significantly lower cost. The companies have been collaborating throughout 2021 on integrating the NanoDx™ System with the CMOS technology. The company anticipates the newly created strategic relationship with Dr. Kelly will help drive commercialization of this leading-edge technology in the in fields of vitro diagnostics and biosensor.
Dr. Kelly has nearly four decades of experience innovating and leading in the Information Technology industry. Throughout his distinguished career, he has held significant technical and business roles driving IBM’s leadership in technologies ranging from semiconductors to supercomputers to artificial intelligence cognitive systems. A champion of IBM’s technical community, he has steered IBM’s leadership in U.S. patents for the last 27 years.
Prior to his retirement in 2020, Dr. Kelly was responsible for helping to guide IBM’s global technical and business success. In this role, he overseed IBM’s enterprise-wide Intellectual Property, Security and Privacy, its academic, industrial, and government partnerships, as well as its technical community. Previously, Dr. Kelly served as senior vice president, Cognitive Solutions, and IBM Research, where he oversaw IBM Watson, the company’s AI platform, and its AI portfolio and investments. Under his leadership, IBM expanded the specialization of IBM Watson into many domains including health, security, analytics, Internet of Things, and financial services.
He also served as senior vice president and director of IBM Research, where he expanded its global footprint across 12 laboratories in 10 countries. He and his team advanced the science of artificial intelligence through Watson, the groundbreaking system that defeated two standing Jeopardy! world champions in 2011.
Dr. Kelly joined IBM in 1980. Between 1980 and 2007, he held numerous management and technical positions related to the development and manufacturing of IBM’s advanced semiconductor technologies. He is a Fellow of the Institute of Electrical and Electronics Engineers (IEEE), a member of the National Academy of Engineering, and has received numerous technology and leadership awards.
Dr. Kelly holds a Bachelor of Science in physics from Union College, and a Master of Science in physics and a Doctorate in materials engineering from Rensselaer Polytechnic Institute. He has also received three honorary Doctoral degrees.
About NanoDx, Inc.
NanoDx, Inc., is a privately held medical device company developing breakthrough, point-of-care diagnostic solutions that address unmet market needs and improve patient outcomes while reducing healthcare costs. The company's flagship product, the NanoDx™ System, is capable of detecting and quantifying biomarkers (analytes) from a small fluid specimen in less than 2 minutes. NanoDx's platform utilizes a proprietary nanosensor technology with a broad range of potential diagnostic applications including COVID-19, Traumatic Brain Injury (TBI), Influenza, Sepsis and Stroke. www.NanoDiagnostics.com